Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239635 | 0.83 | ALDH1A1 (0.57) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11601263 | 0.82 | ALDH1A1 (0.56) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11599368 | 0.80 | ALDH1A1 (0.54) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11601257 | 0.79 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11599362 | 0.79 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL13714410 | 0.79 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL11787140 | 0.79 | ALDH1A1 (0.53) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL6661807 | 0.77 | ALDH1A1 (0.54) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL1692139 | 0.77 | ALDH1A1 (0.71) | ALDH1A1ALOX15CYP3A4TSHRTDP1 | |
| SCHEMBL9341993 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ALOX15CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006017263-A9 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF | TARO PHARMA IND (IL) | 2006-06-01 | — | — | WO | claimed |
| US-20060084632-A1 | Topical gel formulation comprising organophosphate insecticide and its preparation thereof | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2006-04-20 | — | — | US | claimed |
| WO-2006017263-A1 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-02-16 | — | — | WO | claimed |
| US-20150158893-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2015-06-11 | — | — | US | disclosed |
| US-8957238-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2015-02-17 | — | — | US | disclosed |
| US-20130345463-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2013-12-26 | — | — | US | disclosed |
| US-8536155-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2013-09-17 | — | — | US | disclosed |
| US-20120172338-A1 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2012-07-05 | — | — | US | disclosed |
| US-8158139-B2 | Topical gel formulation comprising organophosphate insecticide and preparation thereof | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2012-04-17 | — | — | US | disclosed |
| US-8138366-B2 | Process for the preparation of malathion and its intermediate | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-03-20 | — | — | US | disclosed |
| US-20120053153-A1 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND PREPARATION THEREOF | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2012-03-01 | — | — | US | disclosed |
| EP-1898707-A2 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | Taro Pharmaceuticals North America, Inc. (KY) | 2008-03-19 | — | — | EP | disclosed |
| US-20070065474-A1 | Topical gel formulation comprising organophosphate insecticide and its preparation thereof | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2007-03-22 | — | — | US | disclosed |
| US-20070010496-A1 | Process for Preparing Malathion for Pharmaceutical Use | TARO PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-01-11 | — | — | US | disclosed |
| WO-2007005988-A2 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2007-01-11 | — | — | WO | disclosed |
| US-20060121073-A1 | Topical gel formulation comprising insecticide and its preparation thereof | GOYAL SANDHYA | 2006-06-08 | — | — | US | disclosed |
| WO-2006017263-A9 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF | TARO PHARMA IND (IL) | 2006-06-01 | — | — | WO | disclosed |
| US-20060084632-A1 | Topical gel formulation comprising organophosphate insecticide and its preparation thereof | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2006-04-20 | — | — | US | disclosed |
| WO-2006017263-A1 | TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND ITS PREPARATION THEREOF | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017232-A1 | TOPICAL GEL FORMULATION COMPRISING INSECTICIDE AND ITS PREPARATION THEREOF | TARO PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158893-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | MSMO1, DDO, DCPS | ALDH1A1 1780/4885ALOX15 401/4885CYP3A4 55/4885 |
| US-20130345463-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | MSMO1, DDO, DCPS | ALDH1A1 1780/4885ALOX15 401/4885CYP3A4 55/4885 |
| US-20070010496-A1 | Process for Preparing Malathion for Pharmaceutical Use | MSMO1, DDO, DCPS | ALDH1A1 1780/4885ALOX15 401/4885CYP3A4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.